234 related articles for article (PubMed ID: 36446780)
21. Discovery of a first-in-class EZH2 selective degrader.
Ma A; Stratikopoulos E; Park KS; Wei J; Martin TC; Yang X; Schwarz M; Leshchenko V; Rialdi A; Dale B; Lagana A; Guccione E; Parekh S; Parsons R; Jin J
Nat Chem Biol; 2020 Feb; 16(2):214-222. PubMed ID: 31819273
[TBL] [Abstract][Full Text] [Related]
22. EZH2 promotes invasion and metastasis of laryngeal squamous cells carcinoma via epithelial-mesenchymal transition through H3K27me3.
Luo H; Jiang Y; Ma S; Chang H; Yi C; Cao H; Gao Y; Guo H; Hou J; Yan J; Sheng Y; Ren X
Biochem Biophys Res Commun; 2016 Oct; 479(2):253-259. PubMed ID: 27638307
[TBL] [Abstract][Full Text] [Related]
23. Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2.
Dale B; Anderson C; Park KS; Kaniskan HÜ; Ma A; Shen Y; Zhang C; Xie L; Chen X; Yu X; Jin J
ACS Pharmacol Transl Sci; 2022 Jul; 5(7):491-507. PubMed ID: 35837138
[TBL] [Abstract][Full Text] [Related]
24. EZH2 Promotes Corneal Endothelial Cell Apoptosis by Mediating H3K27me3 and Inhibiting HO-1 Transcription.
Lin Y; Su H; Zou B; Huang M
Curr Eye Res; 2023 Dec; 48(12):1122-1132. PubMed ID: 37800319
[TBL] [Abstract][Full Text] [Related]
25. EZH2 T367 phosphorylation activates p38 signaling through lysine methylation to promote breast cancer progression.
Gonzalez ME; Naimo GD; Anwar T; Paolì A; Tekula SR; Kim S; Medhora N; Leflein SA; Itkin J; Trievel R; Kidwell KM; Chen YC; Mauro L; Yoon E; Andò S; Kleer CG
iScience; 2022 Aug; 25(8):104827. PubMed ID: 35992062
[TBL] [Abstract][Full Text] [Related]
26. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
[TBL] [Abstract][Full Text] [Related]
27. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
28. Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer.
Gao B; Liu X; Li Z; Zhao L; Pan Y
Front Oncol; 2020; 10():600514. PubMed ID: 33665162
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of EZH2 primes the cardiac gene activation via removal of epigenetic repression during human direct cardiac reprogramming.
Tang Y; Zhao L; Yu X; Zhang J; Qian L; Jin J; Lu R; Zhou Y
Stem Cell Res; 2021 May; 53():102365. PubMed ID: 34087994
[TBL] [Abstract][Full Text] [Related]
30. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
Li H; Cai Q; Godwin AK; Zhang R
Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
[TBL] [Abstract][Full Text] [Related]
31. EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells.
Cardenas H; Zhao J; Vieth E; Nephew KP; Matei D
Oncotarget; 2016 Dec; 7(51):84453-84467. PubMed ID: 27563817
[TBL] [Abstract][Full Text] [Related]
32. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
33. Role of EZH2-mediated H3K27me3 in placental ADAM12-S expression: implications for fetoplacental growth.
Zhu YN; Gan XW; Pan F; Ni XT; Myatt L; Wang WS; Sun K
BMC Med; 2022 May; 20(1):189. PubMed ID: 35610640
[TBL] [Abstract][Full Text] [Related]
34. Aberrant overexpression of EZH2 and H3K27me3 serves as poor prognostic biomarker for esophageal squamous cell carcinoma patients.
Liu F; Gu L; Cao Y; Fan X; Zhang F; Sang M
Biomarkers; 2016; 21(1):80-90. PubMed ID: 26631178
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia-activated XBP1s recruits HDAC2-EZH2 to engage epigenetic suppression of ΔNp63α expression and promote breast cancer metastasis independent of HIF1α.
Chen H; Yu S; Ma R; Deng L; Yi Y; Niu M; Xu C; Xiao ZJ
Cell Death Differ; 2024 Apr; 31(4):447-459. PubMed ID: 38413797
[TBL] [Abstract][Full Text] [Related]
36. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
Jiang F; Li Y; Si L; Zhang Z; Li Z
Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
[TBL] [Abstract][Full Text] [Related]
37. The noncanonical role of EZH2 in cancer.
Huang J; Gou H; Yao J; Yi K; Jin Z; Matsuoka M; Zhao T
Cancer Sci; 2021 Apr; 112(4):1376-1382. PubMed ID: 33615636
[TBL] [Abstract][Full Text] [Related]
38. EZH2 regulates expression of FOXC1 by mediating H3K27me3 in breast cancers.
Zheng XJ; Li W; Yi J; Liu JY; Ren LW; Zhu XM; Liu SW; Wang JH; Du GH
Acta Pharmacol Sin; 2021 Jul; 42(7):1171-1179. PubMed ID: 33057161
[TBL] [Abstract][Full Text] [Related]
39. Discovery of precision targeting EZH2 degraders for triple-negative breast cancer.
Wang C; Chen X; Liu X; Lu D; Li S; Qu L; Yin F; Luo H; Zhang Y; Luo Z; Cui N; Kong L; Wang X
Eur J Med Chem; 2022 Aug; 238():114462. PubMed ID: 35623249
[TBL] [Abstract][Full Text] [Related]
40. EZH2 Contributes to Anoikis Resistance and Promotes Epithelial Ovarian Cancer Peritoneal Metastasis by Regulating m6A.
Wang SH; Liu L; Bao KY; Zhang YF; Wang WW; Du S; Jia NE; Suo S; Cai J; Guo JF; Lv G
Curr Med Sci; 2023 Aug; 43(4):794-802. PubMed ID: 37498408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]